Advancing understanding of Alzheimer’s disease using multiomics spatial biology
The complexity of biological systems and diseases, such as Alzheimer’s disease, necessitates spatial multiomics techniques to gain a holistic understanding of cell-cell interactions and communication. A singular approach to spatial multiomics is possible with MALDI Imaging, including label-free imaging of small molecules, lipids, drugs, and glycans. Additionally, with technology developed by AmberGen, Inc., photocleavable mass-tag (PCMT) conjugated affinity probes are available for antibodies, oligos, and lectins.
Key Learning Objectives:
- Learn the spatial biology utility of MALDI Imaging
- Understand multiomics workflows and the applications to disease-based research
Who Should Attend:
- Researchers interested in multiomics brain analysis
- Investigators researching Alzheimer’s disease
Presenter: Mark Lim, Ph.D. (Chief Scientific Officer and Executive VP, AmberGen Inc., Billerica, MA, USA)
Mark Lim Ph.D. is the Chief Scientific Officer and Executive VP at AmberGen Inc. He has over 23 years’ experience in the biotechnology industry and has been awarded over 20 patents which underlie key technologies in the biotechnology industry, including in the fields of proteomics, genomics/transcriptomics, and diagnostics. His early work at AmberGen on photocleavable linkers and protein engineering contributed to the commercialization of a variety of novel reagents including PC-Biotin, PC-Phosphoramidites and fluorescent suppressor tRNAs. Dr. Lim now leads the application of these core AmberGen technologies to multiomic biomarker discovery and biomarker-driven diagnostics.
Presenter: Kate Stumpo, Ph.D. (Senior Market Manager, Bruker Scientific, Billerica, MA, USA)
Dr. Kate Stumpo is a Market Manager which entails messaging and marketing for MALDI Imaging. Dr. Stumpo completed her Ph.D. at Texas A&M University, and is an expert in MALDI applications, including MALDI Imaging.
